- Home
- PEN vs EVR Comparison
PEN vs EVR Comparison
Compare PEN & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- EVR
- Stock Information
- Founded
- PEN 2004
- EVR 1995
- Country
- PEN United States
- EVR United States
- Employees
- PEN N/A
- EVR N/A
- Industry
- PEN Medical/Dental Instruments
- EVR Investment Managers
- Sector
- PEN Health Care
- EVR Finance
- Exchange
- PEN Nasdaq
- EVR Nasdaq
- Market Cap
- PEN 10.0B
- EVR N/A
- IPO Year
- PEN 2015
- EVR 2006
- Fundamental
- Price
- PEN $291.61
- EVR $250.06
- Analyst Decision
- PEN Buy
- EVR Hold
- Analyst Count
- PEN 16
- EVR 6
- Target Price
- PEN $287.07
- EVR $293.60
- AVG Volume (30 Days)
- PEN 509.6K
- EVR 426.1K
- Earning Date
- PEN 02-18-2025
- EVR 02-05-2025
- Dividend Yield
- PEN N/A
- EVR 1.31%
- EPS Growth
- PEN N/A
- EVR 42.54
- EPS
- PEN 0.36
- EVR 9.08
- Revenue
- PEN $1,194,615,000.00
- EVR $2,979,593,000.00
- Revenue This Year
- PEN $13.65
- EVR $23.91
- Revenue Next Year
- PEN $14.30
- EVR $16.96
- P/E Ratio
- PEN $811.72
- EVR $26.89
- Revenue Growth
- PEN 12.86
- EVR 22.82
- 52 Week Low
- PEN $148.00
- EVR $175.24
- 52 Week High
- PEN $310.00
- EVR $324.06
- Technical
- Relative Strength Index (RSI)
- PEN 65.03
- EVR 29.92
- Support Level
- PEN $264.82
- EVR $259.93
- Resistance Level
- PEN $310.00
- EVR $275.69
- Average True Range (ATR)
- PEN 7.93
- EVR 8.54
- MACD
- PEN 2.79
- EVR -2.51
- Stochastic Oscillator
- PEN 64.07
- EVR 10.92
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.